从TPP知识产权谈判审视医疗方法的可专利性  

Review to Patentability of Medical Methods from TPP Intellectual Property Negotiation

作　　者：管荣齐[1] 

机构地区：[1]天津工业大学文法学院

出　　处：《知识产权》2014年第7期92-96,共5页Intellectual Property

基　　金：天津市科技发展战略研究计划项目《职务科技成果转化中利益分享法律问题研究》(批准号:14ZLZLZF05500)之部分成果

摘　　要：美国拟定的TPP知识产权草案要求授予医疗方法专利权,但我国、欧洲以及作为TPP谈判成员国的日本与其不同,其他TPP谈判成员国也有保留意见。虽然如此,与美国、澳大利亚等对医疗方法给予专利保护的国家一致的是,欧洲、日本和我国都在不同方式、不同程度地排除医疗方法可专利性的障碍。但医疗方法可专利性障碍的排除并不是绝对的,并非所有医疗方法都可以授予专利权。建议我国《专利法》和《专利审查指南》删除否定医疗方法可专利性的内容,同时对"不可专利的医疗方法"和"可专利的医疗方法"作出明确的概括性或列举性规定。Medical Methods should be patented according to Trans-Pacific Partnership Intellectual Property Rights Chapter Draft by U. S., but China, Europe and Japan as a member of TPP Negotiators have contrary opinions, and other TPP negotiators also have not exactly the same views. Nevertheless, it is consistent with U. S. and Australia to patent medical methods that Europe, Japan and China are excluding the obstacles to patentability of medical methods in different ways and varying degrees. But the obstacles to patentability of medical methods can not be absolutely excluded; in other words, not all medical methods can be patented. It is recommended that in Chinese Patent Law and Patent Examination Guidelines, the content of denying patentability of medical methods should be deleted, and Non-Patentable Medical Methods and Patentable Medical Methods should be explicitly regulated in the way of peneralizetion or list.

关 键 词：TPP知识产权谈判 医疗方法可专利性 

分 类 号：D923.42[政治法律—民商法学]